Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 10 studies | 41% ± 24% | |
| GABAergic neuron | 8 studies | 38% ± 24% | |
| astrocyte | 8 studies | 24% ± 11% | |
| oligodendrocyte | 7 studies | 27% ± 9% | |
| endothelial cell | 6 studies | 30% ± 9% | |
| oligodendrocyte precursor cell | 6 studies | 25% ± 9% | |
| epithelial cell | 5 studies | 23% ± 7% | |
| neuron | 4 studies | 31% ± 14% | |
| ciliated cell | 4 studies | 23% ± 6% | |
| adipocyte | 4 studies | 19% ± 3% | |
| macrophage | 4 studies | 17% ± 2% | |
| interneuron | 4 studies | 42% ± 22% | |
| GABAergic interneuron | 3 studies | 20% ± 4% | |
| hepatocyte | 3 studies | 28% ± 9% | |
| cardiac muscle cell | 3 studies | 18% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 11 studies | 34% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 6207.24 | 1445 / 1445 | 100% | 62.21 | 183 / 183 |
| ovary | 100% | 5186.93 | 180 / 180 | 100% | 58.27 | 430 / 430 |
| prostate | 100% | 6698.20 | 245 / 245 | 100% | 90.14 | 502 / 502 |
| thymus | 100% | 5504.03 | 653 / 653 | 100% | 86.78 | 605 / 605 |
| uterus | 100% | 5771.85 | 170 / 170 | 100% | 53.78 | 459 / 459 |
| brain | 100% | 8539.73 | 2641 / 2642 | 100% | 86.94 | 705 / 705 |
| intestine | 100% | 6280.23 | 966 / 966 | 100% | 43.58 | 525 / 527 |
| adrenal gland | 100% | 5610.33 | 258 / 258 | 100% | 72.83 | 229 / 230 |
| kidney | 100% | 4554.12 | 89 / 89 | 100% | 51.33 | 897 / 901 |
| skin | 100% | 4960.40 | 1808 / 1809 | 100% | 51.05 | 470 / 472 |
| breast | 100% | 4740.72 | 459 / 459 | 99% | 67.94 | 1112 / 1118 |
| lung | 100% | 3710.20 | 576 / 578 | 100% | 49.01 | 1150 / 1155 |
| pancreas | 99% | 2345.04 | 325 / 328 | 100% | 51.68 | 178 / 178 |
| stomach | 100% | 4158.67 | 358 / 359 | 99% | 46.45 | 284 / 286 |
| bladder | 100% | 5876.38 | 21 / 21 | 99% | 44.55 | 499 / 504 |
| liver | 96% | 2343.35 | 218 / 226 | 93% | 22.34 | 377 / 406 |
| adipose | 100% | 4189.04 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 68.47 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 44.19 | 29 / 29 |
| muscle | 100% | 7216.11 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 3892.01 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 56.60 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 34.22 | 1 / 1 |
| peripheral blood | 100% | 4001.95 | 928 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 5499.37 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 4720.51 | 848 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
| GO_0006515 | Biological process | protein quality control for misfolded or incompletely synthesized proteins |
| GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
| Gene name | ZER1 |
| Protein name | ZER1 protein Zyg-11 related cell cycle regulator Protein zer-1 homolog (Hzyg) (Zyg-11 homolog B-like protein) (Zyg11b-like protein) |
| Synonyms | C9orf60 ZYG ZYG11BL |
| Description | FUNCTION: Serves as substrate adapter subunit in the E3 ubiquitin ligase complex ZYG11B-CUL2-Elongin BC . Acts to target substrates bearing N-terminal degrons for proteasomal degradation with the first four residues of substrates being the key recognition elements . Involved in the clearance of proteolytic fragments generated by caspase cleavage during apoptosis since N-terminal glycine degrons are strongly enriched at caspase cleavage sites. Also important in the quality control of protein N-myristoylation in which N-terminal glycine degrons are conditionally exposed after a failure of N-myristoylation . . |
| Accessions | ENST00000427848.1 ENST00000291900.7 ENST00000414921.5 X6RC68 Q05BR7 X6RD87 Q7Z7L7 |